Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_3

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

NCT04669015
unknownphase_3

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

NCT05172037
unknownphase_3

Novaferon for COVID-19 Treatment Trial (NCTT-005)

NCT04708158
unknownphase_2

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

NCT02068131

Clinical Trials (4)

Showing 4 of 4 trials
NCT04669015Phase 3

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

Unknown
NCT05172037Phase 3

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

Unknown
NCT04708158Phase 3

Novaferon for COVID-19 Treatment Trial (NCTT-005)

Unknown
NCT02068131Phase 2

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4